Mark Mullikin is a highly accomplished professional with a strong educational background in economics and finance. He holds a Postgraduate Diploma in Pharmacoeconomics/Pharmaceutical Economics from UPF Barcelona School of Management, an MBA in Finance with a remarkable GPA of 4.9 out of 5.0 from MIT Sloan School of Management, and a Bachelor's Degree in Economics with a GPA of 3.8 out of 4.0 from the University of Chicago.

Mark has held significant roles in reputable organizations, currently serving as the Vice President of Finance & Investor Relations at Editas Medicine. Prior to his current role, he was the Senior Director of Finance & Investor Relations at the same company. Mark also has a background in health economics and strategic pricing, having worked as the Director in these areas at Novartis.

In addition, Mark has diverse experience in the finance industry, having worked as an Equity Analyst in Healthcare at Adage Capital Management, a Vice President and Senior Research Analyst in Healthcare at Piper Jaffray & Company, and an Engagement Manager at inCode Wireless. He has also worked in strategic planning and consulting roles at Deloitte Consulting and in investment banking at Salomon Smith Barney.

Mark Mullikin's career trajectory reflects his expertise in finance, economics, strategic planning, and healthcare, making him a well-rounded professional with a wealth of experience in various sectors.

Mark's academic achievements, combined with his extensive professional background, position him as a seasoned expert in finance, healthcare economics, strategic pricing, and investor relations.